Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2021 2
2022 1
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants.
Vadrevu KM, Ganneru B, Reddy S, Jogdand H, Raju D, Sapkal G, Yadav P, Reddy P, Verma S, Singh C, Redkar SV, Gillurkar CS, Kushwaha JS, Mohapatra S, Bhate A, Rai SK, Ella R, Abraham P, Prasad S, Ella K. Vadrevu KM, et al. Among authors: gillurkar cs. Sci Rep. 2022 Jul 14;12(1):12038. doi: 10.1038/s41598-022-16097-3. Sci Rep. 2022. PMID: 35835822 Free PMC article. Clinical Trial.
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.
Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, Ganneru B, Sapkal G, Yadav P, Abraham P, Panda S, Gupta N, Reddy P, Verma S, Kumar Rai S, Singh C, Redkar SV, Gillurkar CS, Kushwaha JS, Mohapatra S, Rao V, Guleria R, Ella K, Bhargava B. Ella R, et al. Among authors: gillurkar cs. Lancet Infect Dis. 2021 May;21(5):637-646. doi: 10.1016/S1473-3099(20)30942-7. Epub 2021 Jan 21. Lancet Infect Dis. 2021. PMID: 33485468 Free PMC article. Clinical Trial.
Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5-80 years in India: a phase 3, single-blind, randomised controlled trial.
Thuluva S, Paradkar V, Gunneri S, Mogulla RR, Yerroju V, Dhar C, Ningaiah S, Panchakshari M, Gillurkar CS, Narang M, Kisan SS, Rao AV. Thuluva S, et al. Among authors: gillurkar cs. Lancet Reg Health Southeast Asia. 2025 Jul 24;40:100642. doi: 10.1016/j.lansea.2025.100642. eCollection 2025 Sep. Lancet Reg Health Southeast Asia. 2025. PMID: 40746973 Free PMC article.
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.
Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, Das D, Raju D, Praturi U, Sapkal G, Yadav P, Reddy P, Verma S, Singh C, Redkar SV, Gillurkar CS, Kushwaha JS, Mohapatra S, Bhate A, Rai S, Panda S, Abraham P, Gupta N, Ella K, Bhargava B, Vadrevu KM. Ella R, et al. Among authors: gillurkar cs. Lancet Infect Dis. 2021 Jul;21(7):950-961. doi: 10.1016/S1473-3099(21)00070-0. Epub 2021 Mar 8. Lancet Infect Dis. 2021. PMID: 33705727 Free PMC article. Clinical Trial.